Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (a T-cell engaging bispecific antibody) failed to meet its primary endpoint of overall survival in the United States when compared to standard chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Despite the trial failure, epcoritamab remains approved under accelerated approval and the companies continue to evaluate the therapy in other clinical programs.

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

The European Commission has approved TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. The Phase 3 EPCORE® FL-1 trial demonstrated that the fixed-duration combination therapy reduced disease progression or death risk by 79% compared to standard care, with 96% overall response rate and 74% complete response rate, offering a chemotherapy-free treatment option.

Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% overall response rate and 86% complete response rate with durable remissions and sustained MRD negativity.

Genmab A/S announced the disclosure of share transactions made by managerial employees and their closely associated persons in accordance with EU market abuse regulations. The company also announced a capital increase of 2,346 shares resulting from employee warrant exercises.

The bispecific antibody drug conjugate (BsADC) market is expected to reach over $2 billion by 2030, with the first BsADC approval anticipated by 2028. Over 150 clinical trials are underway globally, with China leading development efforts. Key candidates like Izalontamab brengitecan and JSKN003 are showing positive clinical results in cancer treatment, positioning BsADCs as the next generation of targeted therapies.

The bispecific antibodies market is projected to reach over $60 billion by 2031, growing from $16 billion in 2025. With 18 approved bispecific antibodies and over 550 clinical trials underway, the market is transitioning toward commercial maturity driven by clinical progress in cancer, autoimmune, and inflammatory therapies. Major pharmaceutical players and emerging biotech companies are actively expanding their pipelines through strategic collaborations and technological innovation.

Genmab A/S has completed a share capital reduction by canceling 1.9 million treasury shares, reducing total share capital from DKK 64.25 million to DKK 62.35 million. The reduction was approved at the Annual General Meeting on March 19, 2026, and registered with Danish authorities on April 17, 2026. Nasdaq systems will be updated by April 21, 2026.

Orbis Investment Management Limited has disclosed a 4.99% stake in Genmab A/S as of March 27, 2026, controlling 3,205,763 shares. The announcement was made under Danish Capital Markets Act requirements. Genmab also held its Annual General Meeting on March 19, 2026, where the 2025 Annual Report was approved and discharge was given to the Board of Directors and Executive Management.

Genmab A/S issued a correction to a previous company announcement regarding managerial employee share transactions, correcting the reported share price from DKK 0.00 to DKK 1,867.50. The announcement discloses vesting and net settlement of restricted stock units granted to executives Jan van de Winkel and Anthony Pagano in February 2023.